Login
$ORGO
$0.80 -$0.01 (0.86%) Live

$ORGO SEC Filings

Filed On Filing
05 Nov 2026 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition

CANTON, Mass., (November 5, 2026) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacture, and sale of product solut...

06 Aug 2026 8-K: Entry into a Material Definitive Agreement

Organogenesis Holdings Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with BTIG, LLC (“BTIG”) and Citizens JMP Securities, LLC (“Citizens” and, together with BTIG, the “Agents” and each, an “Agent...

06 Aug 2026 424B5
06 Aug 2026 10-Q
06 Aug 2026 8-K: Results of Operations and Financial Condition

CANTON, Mass., (August 6, 2026) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacture, and sale of product solutio...

16 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

07 May 2026 10-Q
07 May 2026 8-K: Results of Operations and Financial Condition

CANTON, Mass., (May 7, 2026) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacture, and sale of product solutions ...

30 Apr 2026 ARS
30 Apr 2026 Proxy statement: annual meeting on June 15, 2026

CEO pay $6.8M, down 2.6% · say-on-pay vote

24 Apr 2026 Form 4: Grow Brian, Chief Commercial Officer

Received 958 shares by exercise or conversion ($1.19K)

11 Mar 2026 Form 4: Leibowitz Arthur S, Director

Bought 5,000 shares ($13.4K)

11 Mar 2026 Form 4: Driscoll Michael Joseph, Director

Bought 10,000 shares ($26.7K)

03 Mar 2026 Form 4: Cavorsi Robert, Vice President, Strategy

Gave up 700 shares to cover exercise price or tax ($2.25K)

03 Mar 2026 Form 4/A: Montecalvo Antonio S., Vice President, Health Policy

Received 11,330 shares as a grant or award · Gave up 3,778 shares to cover exercise price or tax ($14.5K)

03 Mar 2026 Form 4/A: Grow Brian, Chief Commercial Officer

Received 48,818 shares as a grant or award · Gave up 11,887 shares to cover exercise price or tax ($45.6K)

03 Mar 2026 Form 4/A: Cavorsi Robert, Vice President, Strategy

Received 16,454 shares as a grant or award · Gave up 5,487 shares to cover exercise price or tax ($21.1K)

03 Mar 2026 Form 4/A: Freedman Lori, Chief Admin. and Legal Officer

Received 43,212 shares as a grant or award · Gave up 14,411 shares to cover exercise price or tax ($55.3K)

03 Mar 2026 Form 4/A: Gillheeney Gary S., Director

Received 188,856 shares as a grant or award · Gave up 91,311 shares to cover exercise price or tax ($351K)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support